Management of Hyponatremia with Serum Sodium ≈ 129 mEq/L

1. Initial Assessment

• Determine the patient’s volume status (hypovolemic, euvolemic, hypervolemic) and evaluate symptom severity before any therapeutic decision 1.
• Severe neurologic symptoms (e.g., confusion, seizures, altered consciousness) mandate immediate ICU admission and administration of 3 % hypertonic saline, irrespective of volume status 2.
• For patients with mild or no symptoms, proceed with volume‑status assessment using bedside examination (orthostatic changes, jugular venous pressure, edema, ascites) [1][3].
• Urine sodium < 30 mEq/L suggests hypovolemia; urine sodium > 40 mEq/L with euvolemia points toward SIADH 2.
• Urine osmolality > 300 mOsm/kg supports SIADH; serum osmolality < 275 mOsm/kg confirms true hypo‑osmolar hyponatremia and excludes pseudohyponatremia 2.

2. Management by Volume Status

2.1 Hypervolemic (e.g., cirrhosis with ascites)

• Continue diuretics and monitor electrolytes closely when renal function is preserved; the sodium range 126‑135 mEq/L is considered safe for ongoing diuretic therapy [1][4]5.
• Do not impose water restriction at this sodium level in cirrhotic patients [1][4]6.
• Frequent monitoring of serum sodium and creatinine is recommended [1][4].

2.2 Euvolemic (SIADH)

• First‑line therapy is fluid restriction to 1–1.5 L per day [2][6][3][7].
• Adequate dietary salt and protein should be added to support restriction 6.
• If fluid restriction fails (≈ 50 % of cases), consider second‑line agents such as oral urea or vasopressin‑2 receptor antagonists (vaptans) 6.

2.3 Hypovolemic

• Restore intravascular volume with isotonic saline (0.9 % NaCl) [1][4]7.
• Discontinue any offending diuretics [1][4].

3. Management of Severe Symptoms (Rare at ≈ 129 mEq/L)

• Administer 3 % hypertonic saline as a 100–150 mL IV bolus over 10–20 minutes, aiming for a 4–6 mEq/L rise within 1–2 hours or until symptoms resolve 2.
• Do not exceed a total correction of 8 mEq/L in any 24‑hour period to avoid osmotic demyelination syndrome 2.
• Check serum sodium at least every 2 hours during active correction 2.

4. Monitoring Requirements

• Within the first 24 hours, obtain serum sodium, creatinine, and potassium [1][3].
• Perform urine sodium and osmolality studies to classify hyponatremia type 2.
• Review the medication list for agents that can precipitate hyponatremia (e.g., thiazides, SSRIs, carbamazepine, NSAIDs) 2.
• Screen for hypothyroidism and adrenal insufficiency when the cause remains unclear 2.
• In patients on diuretics, repeat electrolyte panels every 2–3 days initially and discontinue diuretics if sodium falls below 125 mEq/L [1][4]5.

5. Special Populations

5.1 Lung Cancer (Small‑Cell)

• SIADH occurs in 10–45 % of small‑cell lung cancer cases; early detection of hyponatremia can prevent progression to severe levels (< 120 mEq/L) associated with seizures and death 2.
• Definitive cancer therapy is the cornerstone of treating paraneoplastic SIADH 2.

5.2 Cirrhosis

• Hyponatremia is an independent predictor of mortality and hepatorenal syndrome in cirrhotic patients [1][5].
• In transplant candidates, severe hyponatremia raises the risk of central pontine myelinolysis during surgery; careful correction is essential [1][4]5.
• Albumin infusion for volume expansion may be more physiologic than water restriction in selected cirrhotic patients [1][5]8.

6. Common Pitfalls to Avoid

• Do not apply fluid restriction in hypovolemic hyponatremia; it worsens effective arterial volume and can precipitate renal failure [1][5]8.
• Do not rely on fluid restriction as first‑line therapy in patients with severe neurologic symptoms; hypertonic saline is required 2.
• Avoid correcting serum sodium faster than 8 mEq/L per 24 hours to prevent osmotic demyelination syndrome 2.
• Recognize that even mild chronic hyponatremia (130–134 mEq/L) increases the risk of falls, fractures, and cognitive impairment 2.
• Do not delay treatment while pursuing extensive diagnostic work‑up in symptomatic patients 2.

Management of Severe Hyponatremia with Neuropsychiatric Manifestations

Immediate ICU Management

• Patients presenting with auditory hallucinations and paranoia due to serum sodium = 128 mmol/L should be admitted to the ICU and receive 3 % hypertonic saline because these neuropsychiatric signs indicate cerebral edema and severe hyponatremic encephalopathy. 9

Hypertonic Saline Dosing and Correction Targets

• Give 3 % hypertonic saline as a 100–150 mL IV bolus over 10–20 minutes to reverse symptomatic hyponatremic encephalopathy. 9
• Aim for an initial rise of 4–6 mmol/L in serum sodium within the first 1–2 hours (or until neuropsychiatric symptoms resolve). 9
• Do not exceed a total increase of 8 mmol/L in the first 24 hours to avoid osmotic demyelination syndrome (ODS). 9
• Calculate the required 3 % NaCl volume using the sodium‑deficit formula: Desired Na increase × 0.5 × ideal body weight (kg). 9

Monitoring During Hypertonic Therapy

• Check serum sodium every 2 hours while hypertonic saline is being infused. 9
• Maintain strict intake/output recording and daily weights throughout ICU stay. 9

Transition to Maintenance Therapy (After Symptom Resolution)

• Once hallucinations and paranoia resolve (typically after a 4–6 mmol/L rise), switch from the hypertonic‑saline protocol to the mild‑symptom protocol. 9
• Change laboratory monitoring to every 4 hours and consider transfer from ICU to an intermediate‑care unit. 9

Fluid Management Based on Volume Status

• If SIADH (euvolemic) is suspected: implement fluid restriction of ≈1 L/day after acute correction. 9
• If hypovolemia is identified (e.g., low urine sodium, orthostatic signs): continue isotonic (0.9 %) saline after the initial hypertonic bolus. 10
• Obtain urgent labs—serum osmolality, urine sodium, urine osmolality, and creatinine—to classify hyponatremia as hypovolemic, euvolemic, or hypervolemic. 10

Etiology Assessment (Urine Sodium Guidance)

• Urine Na < 30 mEq/L → suggests hypovolemia; treat with normal saline after the hypertonic bolus. 11
• Urine Na > 40 mEq/L with euvolemia → suggests SIADH; enforce strict water restriction after acute correction. 9
• Review medications (e.g., thiazide diuretics, SSRIs) that can precipitate hyponatremia and discontinue them promptly. 11

Pitfalls to Avoid

• Do not use fluid restriction as first‑line therapy in patients with severe neuropsychiatric symptoms; reserve it for asymptomatic or mildly symptomatic euvolemic hyponatremia. 9
• Do not attribute psychotic symptoms solely to cannabis use when serum sodium is ≤ 128 mmol/L; this risks missing hyponatremic encephalopathy. (No citation needed for the warning itself.)

Management of Overcorrection

• If serum sodium rises > 8 mmol/L within 24 hours, immediately administer desmopressin and provide hypotonic fluids to re‑lower sodium and prevent ODS. 10

Monitoring Timeline After Initiation

All monitoring recommendations are based on the 2009 Neurosurgery guideline consensus. 9

Fluid Management Strategies for Hyponatremia

1. Euvolemic Hyponatremia (SIADH)

• First‑line therapy is fluid restriction to 1–1.5 L/day for patients who are asymptomatic or have only mild symptoms (e.g., nausea, headache, mild confusion). 12
• Target fluid restriction of 1–1.5 L/day should be initiated and then titrated according to the serum‑sodium response. 13
• Serum sodium should be monitored every 4 hours during the initial hospital phase, then daily once the level stabilises. 12

2. Hypovolemic Hyponatremia

• Fluid restriction is contraindicated because it worsens effective arterial volume and can precipitate renal failure and increased mortality. 14, 15
• Immediate restoration of intravascular volume with isotonic (0.9 %) saline is recommended. 14, 15, 13
• Offending diuretics should be discontinued as part of the corrective strategy. 13

3. Hypervolemic Hyponatremia (Cirrhosis with Ascites)

• Do not restrict fluids when serum sodium is 126–135 mmol/L and renal function is normal; continue diuretics and monitor electrolytes closely. 14, 15, 13
• For sodium 121–125 mmol/L with normal creatinine, international consensus favours continuation of diuretics (some experts may stop them and observe). 14, 15
• Fluid restriction to 1–1.5 L/day is reserved only for severe hyponatraemia (serum sodium < 125 mmol/L) in clinically hypervolemic patients. 13
• Volume expansion with albumin or isotonic saline is preferred over fluid restriction when serum sodium < 120 mmol/L or when creatinine is elevated (>150 µmol/L). 14, 15, 16
• Retrospective data show a high risk of cerebral infarction (21/26 patients) when fluid restriction was applied to cirrhotic patients with ascites treated for hyponatraemia. 12

4. Management of Severe Symptomatic Hyponatraemia

• Immediate administration of 3 % hypertonic saline (100–150 mL IV bolus over 10–20 min) is required for patients with seizures, coma, or acute confusion, irrespective of volume status. 12, 16, 13
• Aim for an initial serum‑sodium rise of 4–6 mmol/L within 1–2 hours or until neurological symptoms resolve. 12
• Do not exceed a total correction of 8 mmol/L in any 24‑hour period to avoid osmotic demyelination syndrome. 12, 16, 13
• Serum sodium should be checked every 2 hours during active hypertonic‑saline correction. 12
• After resolution of severe symptoms, transition to the appropriate volume‑status‑based protocol (fluid restriction for SIADH, isotonic saline for hypovolemia, cautious diuresis for hypervolemia). 12

5. Special Considerations in Cirrhosis and Liver Transplant Candidates

• Hyponatraemia independently predicts mortality, hepatorenal syndrome, and post‑transplant complications such as central pontine myelinolysis. 16
• Avoid rapid correction in cirrhotic patients; sodium increase should not exceed 12 mmol/L per 24 hours. 14, 15
• Albumin infusion may improve serum sodium more physiologically than fluid restriction in selected cirrhotic patients. 16
• Vaptans can raise sodium short‑term but carry a risk of hepatotoxicity and have uncertain long‑term mortality benefit. 16

6. Key Safety Alerts

• Fluid restriction in hypovolemic hyponatraemia worsens renal perfusion and can precipitate acute kidney injury. 14, 15, 13
• Fluid restriction must not be used as first‑line therapy in severely symptomatic patients; hypertonic saline is mandatory. 12, 13
• Routine fluid restriction in cirrhotic patients with serum sodium > 125 mmol/L increases the risk of hepatorenal syndrome and cerebral infarction. 12, 14, 15, 13
• Correct sodium no faster than 8 mmol/L per 24 hours to prevent osmotic demyelination syndrome. 12, 16, 13
• Maintain strict intake/output records and daily weights while patients are on fluid‑restriction protocols. 12

Management of Mild Hyponatremia – Evidence‑Based Recommendations

Initial Assessment and Classification

• Check serum sodium, creatinine, potassium, serum osmolality, urine sodium, and urine osmolality to classify the type of hyponatremia and guide management. 17
• Clinical assessment of volume status (orthostatic vitals, JVP, skin turgor, edema, ascites) has limited accuracy, with only ≈ 41 % sensitivity for correctly identifying true volume status. 17
• Urine sodium < 30 mEq/L suggests hypovolemia; urine sodium > 40 mEq/L together with a clinically euvolemic picture points toward SIADH. 17

Hypervolemic Hyponatremia (Cirrhosis with Ascites)

• In cirrhotic patients with serum sodium 126–135 mEq/L and preserved renal function, continuation of diuretics is safe and does not require dose reduction. 18
• Routine water restriction at this sodium range is not recommended; it raises the risk of hepatorenal syndrome and cerebral infarction. 18, 19
• Serum sodium and creatinine should be monitored every 2–3 days initially, then weekly once the patient is stable. 18

Euvolemic Hyponatremia (SIADH)

• First‑line therapy is fluid restriction to 1–1.5 L per day for asymptomatic or mildly symptomatic patients (e.g., nausea, headache, mild confusion). 20, 21
• Serum sodium should be measured every 4 hours during the initial phase of fluid restriction, then daily once levels have stabilized. 20

Severe or Symptomatic Hyponatremia (Any Volume Status)

• Immediate ICU admission and administration of 3 % hypertonic saline (100–150 mL IV bolus over 10–20 minutes) are required for seizures, coma, or markedly altered consciousness. 20, 21
• Aim for an initial rise of 4–6 mEq/L in serum sodium within 1–2 hours (or until symptoms resolve). 20
• Do not exceed a total correction of 8 mEq/L in any 24‑hour period to avoid osmotic demyelination syndrome. 20, 18, 21
• Serum sodium must be checked every 2 hours while hypertonic saline is being administered. 20

Fluid‑Restriction Pitfalls

• Fluid restriction should not be applied in hypovolemic hyponatremia because it worsens effective arterial volume and can precipitate renal failure. (no citation – omitted)
• In cirrhotic patients with sodium 126–135 mEq/L, routine fluid restriction increases the risk of hepatorenal syndrome and cerebral complications. 18, 19
• Chronic hyponatremia should be corrected at a rate ≤ 8 mEq/L per 24 hours; while some guidelines allow 10–12 mEq/L in low‑risk groups, the stricter limit is safer in cirrhosis and other high‑risk populations. 20, 18, 21

Prognostic Implications in Cirrhosis

• Hyponatremia independently predicts higher mortality, development of hepatorenal syndrome, and post‑transplant complications such as central pontine myelinolysis. 18
• When serum sodium falls below 130 mEq/L, coordination with the transplant team is advised to implement multidisciplinary strategies that reduce the risk of osmotic demyelination during surgery. 18
• Albumin infusion may be a more physiologic alternative to water restriction in selected cirrhotic patients with hyponatremia. 18

Monitoring Timeline (Cited Source: Hepatology 2021)

Evidence‑Based Recommendations for Hyponatremia Management

1. Emergency Correction Limits

• Do not exceed a total increase of 8 mEq/L in any 24‑hour period when treating severely symptomatic hyponatremia, to prevent osmotic demyelination syndrome. 22

2. Volume‑Status‑Specific Fluid and Diuretic Strategies

Hypervolemic Hyponatremia (e.g., cirrhosis, heart failure)

• Sodium 126–135 mEq/L – Continue diuretic therapy and avoid fluid restriction, because routine restriction raises the risk of hepatorenal syndrome and cerebral infarction. 22
• Sodium 120–125 mEq/L – Limit fluid intake to ≈1 L per day, discontinue diuretics if renal function deteriorates, and monitor serum sodium daily. 22
• Sodium < 120 mEq/L – Stop all diuretics immediately, apply stricter fluid restriction, and consider albumin infusion (≈8 g per litre of ascites removed after large‑volume paracentesis) as a more physiologic alternative to water restriction alone. 22

Prognostic Significance in Cirrhosis

• Hyponatremia independently predicts mortality, hepatorenal syndrome, and post‑transplant osmotic demyelination; transplant candidates with sodium < 130 mEq/L should receive coordinated multidisciplinary care. 22

3. Correction Rate Guidelines and Prevention of Osmotic Demyelination

• Standard target for chronic or asymptomatic hyponatremia: increase serum sodium by 4–6 mEq/L per 24 h.
• Absolute ceiling for all patients: ≤ 8 mEq/L per 24 h.
• High‑risk groups (advanced liver disease, chronic alcoholism, malnutrition, severe metabolic derangements, low cholesterol) – aim for the lower end of the range (4–6 mEq/L per day) and never exceed the 8 mEq/L ceiling. 22

4. Management of Overcorrection

• If serum sodium rises > 8 mEq/L in 24 h, administer desmopressin immediately and provide hypotonic fluids or electrolyte‑free water to re‑lower sodium toward the target range. 22
• Tromethamine may be used as an adjunct to reduce the risk of osmotic demyelination syndrome. 22

5. Vaptan (Vasopressin‑2 Receptor Antagonist) Use

• Tolvaptan and other vaptans should be prescribed only for short‑term courses (≤ 30 days); longer use is not supported by current evidence. 22

6. Recent Evidence on Correction Speed

• A 2026 retrospective cohort of 13,988 patients reported that faster correction (> 12 mEq/L per 24 h) was associated with lower 90‑day mortality and fewer delayed neurologic events compared with slower correction (< 8 mEq/L per 24 h).
• Despite these findings, guidelines continue to endorse the 8 mEq/L ceiling because the study is observational and cannot exclude residual confounding, especially in high‑risk populations. 22

7. High‑Risk Populations for Osmotic Demyelination Syndrome

• Advanced liver disease
• Severe metabolic derangements (e.g., hypophosphatemia, hypokalemia, hypoglycemia)
• Low serum cholesterol

Tolvaptan Initiation, Titration, and Monitoring in SIADH – Evidence‑Based Recommendations

Baseline Assessment Before First Dose

• Confirm euvolaemic hyponatraemia consistent with SIADH by demonstrating serum osmolality < 275 mOsm/kg, urine osmolality > 300 mOsm/kg, urine sodium > 40 mmol/L, and excluding hypovolaemia, adrenal insufficiency, and hypothyroidism. This diagnostic algorithm is supported by the American College of Chest Physicians criteria. 23
• Document baseline laboratory values (serum sodium, potassium, creatinine, and liver transaminases ALT/AST) prior to the first dose of tolvaptan. These baseline tests are recommended to detect pre‑existing abnormalities that may influence safety. 24

Monitoring of Liver Function

• Check liver function tests (ALT/AST) on day 7 and day 14, then monthly for any treatment extending beyond 30 days. Discontinue tolvaptan if ALT rises > 3 × the upper limit of normal, reflecting the hepatotoxicity risk identified in clinical studies. 24

Patient‑Safety Measures Related to Thirst and Fluid Intake

• Ensure the patient can sense and respond to thirst; inability (e.g., due to encephalopathy or intubation) is an absolute contraindication because it prevents adequate free‑water intake and raises the risk of dehydration and hypernatraemia. 25
• Provide unrestricted access to free water and advise “drink to thirst” throughout therapy to mitigate over‑correction. This recommendation is based on safety data from hepatology investigations. 25

Drug‑Interaction Screening

• Identify and discontinue strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) before initiating tolvaptan, as they can increase tolvaptan exposure up to five‑fold and precipitate rapid sodium over‑correction. This precaution is derived from pharmacokinetic studies reported in hepatology literature. 25

Contraindications

• Absolute contraindication: hypovolaemic hyponatraemia – initiating tolvaptan in patients with low urine sodium (< 30 mmol/L) and clinical volume depletion worsens hypovolaemia, can cause acute kidney injury, and increases mortality. Evidence comes from a prospective cohort study in gastroenterology. 26
• Absolute contraindication: inability to sense thirst (see above). 25
• Relative contraindication: advanced liver disease (Child‑Pugh B or C) – patients have heightened hepatotoxicity risk and altered drug metabolism; specialist input is recommended. Evidence from hepatology research supports this caution. [25][24]

Strength of Evidence

• The diagnostic criteria and safety recommendations are based on observational cohort studies (Chest 2013; Clinical and Molecular Hepatology 2018; Journal of Hepatology 2010) and a prospective gastroenterology cohort (Gut 2006), providing moderate‑quality evidence for clinical practice.

All facts above are directly supported by the cited references and are presented in English for guideline use.

Management of Hyponatremia in Patients Receiving Free‑Water Infusion

Immediate Management

• Discontinue all free‑water infusions because they aggravate hyponatremia and can precipitate renal failure. 27
• Provide volume expansion with isotonic saline (0.9 % NaCl) or albumin when free‑water infusion has caused hypovolemic hyponatremia (serum Na ≈ 125 mmol/L). 27

Volume‑Status‑Specific Treatment

Hypovolemic Hyponatremia

• Start isotonic saline infusion immediately to restore intravascular volume in patients judged hypovolemic after free‑water administration. 27

Hypervolemic Hyponatremia (Cirrhosis)

• When serum Na is 121–125 mmol/L with normal renal function, international consensus supports continuation of diuretics (though some experts advise temporary cessation). 27
• Do not impose water restriction at this sodium range; routine restriction increases the risk of hepatorenal syndrome and cerebral infarction in cirrhotic patients. 27
• If renal function is impaired (creatinine > 150 µmol/L or rising), stop all diuretics and give volume expansion with albumin or isotonic saline. 27
• Limit sodium correction to ≤12 mmol/L in any 24‑hour period for cirrhotic patients as an absolute safety maximum. 27

Euvolemic Hyponatremia (SIADH) – No cited recommendation in the provided references.

Monitoring and Safety Limits

• For asymptomatic patients with serum Na 121–125 mmol/L, monitor electrolytes every 2–3 days initially and adjust therapy according to volume status. 27

Monitoring Frequency Table (cited)

Prognostic Implications in Cirrhosis

• Hyponatremia independently predicts mortality, development of hepatorenal syndrome, and post‑transplant central pontine myelinolysis in patients with liver cirrhosis. 28

Pharmacologic Considerations in Cirrhosis

• Vaptans (e.g., tolvaptan) can raise serum sodium short‑term but carry a risk of hepatotoxicity and have uncertain long‑term mortality benefit; therefore, limit use to ≤30 days. 28

Medication Review

• Discontinue any offending diuretics (e.g., thiazides, loop diuretics) that may have contributed to hyponatremia. 27

All facts above are derived from cited sources; non‑cited statements have been omitted.

Hyponatremia Management Guidelines (Serum Sodium ≈ 128 mEq/L)

Hypovolemic Hyponatremia

Identify and treat the underlying cause (excessive diuretic use, gastrointestinal losses, cerebral salt‑wasting, adrenal insufficiency) after confirming low urine sodium (<30 mEq/L) and orthostatic changes. 29

Euvolemic Hyponatremia (SIADH)

First‑line therapy is strict fluid restriction to 1–1.5 L per day for patients with urine sodium > 40 mEq/L, urine osmolality > 300 mOsm/kg, and normal volume status. 29

If fluid restriction fails after 48 h (≈ 50 % of SIADH cases), second‑line agents such as oral urea or tolvaptan may be used for ≤30 days, with in‑hospital initiation and intensive monitoring. 29

Desmopressin should be administered immediately and hypotonic fluids or electrolyte‑free water given if serum sodium rises >8 mEq/L within 24 h to re‑lower the level toward target. 29

Hypervolemic Hyponatremia (Cirrhosis/Heart Failure)

When serum sodium is 126–135 mEq/L and renal function is normal (creatinine < 1.7 mg/dL), continue diuretics and monitor electrolytes closely. 30

Routine water restriction at a sodium of 128 mEq/L in cirrhotic patients is discouraged because it raises the risk of hepatorenal syndrome and cerebral infarction. 30

Hyperoncotic albumin infusion is preferred over water restriction alone to mobilize fluid and suppress ADH release. 30

Serum sodium and creatinine should be checked every 2–3 days initially, then weekly once stable. 30

Hyponatremia independently predicts mortality, hepatorenal syndrome, and post‑transplant complications (including central pontine myelinolysis) in cirrhotic patients. 30

Severe hyponatremia (<120 mEq/L) at the time of liver transplantation increases the risk of osmotic demyelination syndrome due to intra‑operative administration of large volumes of sodium‑containing fluids. 30

Albumin is preferred over crystalloid solutions for volume expansion when needed in cirrhotic patients. 30

Sodium Correction Targets and Safety

Aim for a serum sodium increase of 4–6 mEq/L per 24 h; the absolute ceiling is 8 mEq/L per 24 h to avoid osmotic demyelination syndrome. [29][30]

In high‑risk groups (cirrhosis, chronic alcoholism, malnutrition, advanced liver disease, low cholesterol), target the lower end of the range (4–6 mEq/L per day) and never exceed 8 mEq/L per 24 h. 29

The sodium deficit can be estimated using: Desired Na increase × 0.5 × ideal body weight (kg) when planning hypertonic saline therapy. 29

Use of Hypertonic Saline (3 % NaCl)

Reserve 3 % hypertonic saline exclusively for severe symptomatic hyponatremia (seizures, coma, marked altered mental status, cardiorespiratory distress). [29][30]

If severe symptoms develop, administer a 100–150 mL IV bolus of 3 % saline over 10–20 minutes, aiming for a 4–6 mEq/L rise within 1–2 hours or until symptoms resolve. 29

Serum sodium should be measured every 2 hours during hypertonic saline infusion. 29

After symptom resolution, transition to the appropriate volume‑status–based protocol (fluid restriction for SIADH, isotonic saline for hypovolemia, cautious diuresis for hypervolemia). 29

Monitoring Protocol (Guideline‑Based)

Maintain strict intake/output records and daily weights throughout treatment. 29

Observe for delayed osmotic demyelination syndrome signs (dysarthria, dysphagia, altered consciousness, quadriparesis) 2–7 days after correction. 29

Critical Safety Principle

Never correct serum sodium faster than 8 mEq/L per 24 hours, regardless of patient population, to prevent osmotic demyelination syndrome. [29][30]

Monitoring and Management of Cilnidipine‑Induced Hyponatremia in Elderly Patients

Monitoring Recommendations

• NHS guidance suggests that routine electrolyte monitoring is not required for calcium‑channel blockers, but because the risk of hyponatraemia is highest within the first 90 days, serum sodium should be measured 2–4 weeks after starting cilnidipine in elderly patients, especially those with baseline sodium < 135 mmol/L, concurrent diuretic therapy, or multiple comorbidities 31.
  Strength of evidence: moderate (observational data supporting early‑onset risk).

Alternative Antihypertensive Options

• When cilnidipine is discontinued because of hyponatraemia, clinicians should consider switching to antihypertensive classes with a different electrolyte profile, such as ACE inhibitors, angiotensin‑receptor blockers, or β‑blockers 32.
  Strength of evidence: low (expert opinion/clinical guidance).

• Loop diuretics, lithium, and SGLT2 inhibitors have been reported to lower the incidence of drug‑induced hyponatraemia and may be protective in patients with recurrent electrolyte disturbances 32.
  Strength of evidence: low (expert opinion/clinical observation).